UNLABELLED: In September 2015, the member states of the United Nations endorsed sustainable development goals (SDG) for 2030 that aspire to human rights-centered approaches to ensuring the health and well-being of all people. The SDGs embody both the UN Charter values of rights and justice for all and the responsibility of states to rely on the best scientific evidence as they seek to better humankind. In April 2016, these same states will consider control of illicit drugs, an area of social policy that has been fraught with controversy, seen as inconsistent with human rights norms, and for which scientific evidence and public health approaches have arguably played too limited a role. The previous UN General Assembly Special Session (UNGASS) on drugs in 1998 – convened under the theme “a drug-free world, we can do it!” – endorsed drug control policies based on the goal of prohibiting all use, possession, production, and trafficking of illicit drugs. This goal is enshrined in national law in many countries. In pronouncing drugs a “grave threat to the health and well-being of all mankind,” the 1998 UNGASS echoed the foundational 1961 convention of the international drug control regime, which justified eliminating the “evil” of drugs in the name of “the health and welfare of mankind.” But neither of these international agreements refers to the ways in which pursuing drug prohibition itself might affect public health. The “war on drugs” and “zero-tolerance” policies that grew out of the prohibitionist consensus are now being challenged on multiple fronts, including their health, human rights, and development impact. The Johns Hopkins – Lancet Commission on Drug Policy and Health has sought to examine the emerging scientific evidence on public health issues arising from drug control policy and to inform and encourage a central focus on public health evidence and outcomes in drug policy debates, such as the important deliberations of the 2016 UNGASS on drugs. The Johns Hopkins-Lancet Commission is concerned that drug policies are often colored by ideas about drug use and drug dependence that are not scientifically grounded. The 1998 UNGASS declaration, for example, like the UN drug conventions and many national drug laws, does not distinguish between drug use and drug abuse. A 2015 report by the UN High Commissioner for Human Rights, by contrast, found it important to emphasize that “[d]rug use is neither a medical condition nor does it necessarily lead to drug dependence.” The idea that all drug use is dangerous and evil has led to enforcement-heavy policies and has made it difficult to see potentially dangerous drugs in the same light as potentially dangerous foods, tobacco, alcohol for which the goal of social policy is to reduce potential harms. HEALTH IMPACT OF DRUG POLICY BASED ON ENFORCEMENT OF PROHIBITION: The pursuit of drug prohibition has generated a parallel economy run by criminal networks. Both these networks, which resort to violence to protect their markets, and the police and sometimes military or paramilitary forces that pursue them contribute to violence and insecurity in communities affected by drug transit and sales. In Mexico, the dramatic increase in homicides since the government decided to use military forces against drug traffickers in 2006 has been so great that it reduced life expectancy in the country. Injection of drugs with contaminated equipment is a well-known route of HIV exposure and viral hepatitis transmission. People who inject drugs (PWID) are also at high risk of tuberculosis. The continued spread of unsafe injection-linked HIV contrasts the progress that has been seen in reducing sexual and vertical transmission of HIV in the last three decades. The Commission found that that repressive drug policing greatly contributes to the risk of HIV linked to injection. Policing may be a direct barrier to services such as needle and syringe programmes (NSP) and use of non-injected opioids to treat dependence among those who inject opioids, known as opioid substitution therapy (OST). Police seeking to boost arrest totals have been found to target facilities that provide these services to find, harass, and detain large numbers of people who use drugs. Drug paraphernalia laws that prohibit possession of injecting equipment lead PWID to fear carrying syringes and force them to share equipment or dispose of it unsafely. Policing practices undertaken in the name of the public good have demonstrably worsened public health outcomes. Amongst the most significant impacts of pursuit of drug prohibition identified by the Commission with respect to infectious disease is the excessive use of incarceration as a drug-control measure. Many national laws impose lengthy custodial sentences for minor, non-violent drug offenses; people who use drugs (PWUD) are over-represented in prison and pretrial detention. Drug use and drug injection occur in prisons, though their occurrence is often denied by officials. HIV and hepatitis C virus (HCV) transmission occurs among prisoners and detainees, often complicated by co-infection with TB and in many places multidrug-resistant TB, and too few states offer prevention or treatment services in spite of international guidelines that urge comprehensive measures, including provision of injection equipment, for people in state custody. Mathematical modelling undertaken by the Commission illustrates that incarceration and high HCV risk in the post-incarceration period can contribute importantly to national HCV incidence amongst PWID in a range of countries with varying levels of incarceration, different average prison sentences, durations of injection, and OST coverage levels in prison and following release. For example, in Thailand where PWID may spend nearly half their injection careers in prison, an estimated 63% of incident HCV infection could occur in prison. In Scotland, where prison sentences are shorter for PWUD and OST coverage is relatively high in prison, an estimated 54% of incident HCV infection occurs in prison, but as much as 21% may occur in the high-risk post-release period. These results underscore the importance of alternatives to prison for minor drug offences, ensuring access to OST in prison, and a seamless link from prison services to OST in the community. The evidence also clearly demonstrates that drug law enforcement has been applied in a discriminatory way against racial and ethnic minorities in a number of countries. The US is perhaps the best documented but not the only case of racial biases in policing, arrest, and sentencing. In 2014, African American men were more than five times more likely than whites to be incarcerated in their lifetime, though there is no significant difference in rates of drug use among these populations. The impact of this bias on communities of people of color is inter-generational and socially and economically devastating. The Commission also found significant gender biases in current drug policies. Of women in prison and pretrial detention around the world, a higher percentage are detained because of drug infractions than is the case for men. Women involved in drug markets are often on the bottom rungs – as couriers or drivers – and may not have information about major traffickers to trade as leverage with prosecutors. Gender and racial biases have marked overlap, making this an intersectional threat to women of color, their children, families, and communities. In both prison and the community, HIV, HCV and TB programmes for PWUD – including testing, prevention and treatment – are gravely underfunded at the cost of preventable death and disease. In a number of middle-income countries where large numbers of PWUD live, HIV and TB programmes for PWUD that were expanded with support from the Global Fund to Fight AIDS, TB and Malaria have lost funding due to changes in the Fund’s eligibility criteria. There is an unfortunate failure to emulate the example of Western European countries that have eliminated unsafe injection-linked HIV as a public health problem by sustainably scaling up prevention and care and enabling minor offenders to avert prison. Political resistance to harm reduction measures dismisses strong evidence of their effectiveness and cost-effectiveness. Mathematical modeling shows that if OST, NSP and antiretroviral therapy for HIV are all available, even if the coverage of each of them is not over 50%, their synergy can lead to effective prevention in a foreseeable future. PWUD are often not seen to be worthy of costly treatments, or they are thought not to be able to adhere to treatment regimens in spite of evidence to the contrary. Lethal drug overdose is an important public health problem, particularly in light of rising consumption of heroin and prescription opioids in some parts of the world. Yet the Commission found that the pursuit of drug prohibition can contribute to overdose risks in numerous ways. It creates unregulated illegal markets in which it is impossible to control adulterants of street drugs that add to overdose risk. Several studies also link aggressive policing to rushed injection and overdose risk. People with a history of drug use, over-represented in prison because of prohibitionist policies, are at extremely high risk of overdose when released from state custody. Lack of ready access to OST also contributes to injection of opioids, and bans on supervised injection sites cut off an intervention that has proven very effective in reducing overdose deaths. Restrictive drug policies also contribute to unnecessary controls on naloxone, a medicine that can reverse overdose very effectively. Though a small percentage of PWUD will ever need treatment for drug dependence, that minority faces enormous barriers to humane and affordable treatment in many countries. There are often no national standards for quality of drug dependence treatment and no regular monitoring of practices. In too many countries, beatings, forced labor, and denial of health care and adequate sanitation are offered in the name of treatment, including in compulsory detention centres that are more like prisons than treatment facilities. Where there are humane treatment options, it is often the case that those most in need of it cannot afford it. In many countries, there is no treatment designed particularly for women, though it is known that women’s motivations for and physiological reactions to drug use differ from those of men. The pursuit of the elimination of drugs has led to aggressive and harmful practices targeting people who grow crops used in the manufacture of drugs, especially coca leaf, opium poppy, and cannabis. Aerial spraying of coca fields in the Andes with the defoliant glyphosate (N-(phosphonomethyl glycine) has been associated with respiratory and dermatological disorders and with miscarriages. Forced displacement of poor rural families who have no secure land tenure exacerbates their poverty and food insecurity and in some cases forces them to move their cultivation to more marginal land. Geographic isolation makes it difficult for state authorities to reach drug crop cultivators in public health and education campaigns and it cuts cultivators off from basic health services. Alternative development programmes meant to offer other livelihood opportunities have poor records and have rarely been conceived, implemented, or evaluated with respect to their impact on people’s health. Research on drugs and drug policy has suffered from the lack of a diversified funding base and assumptions about drug use and drug pathologies on the part of the dominant funder, the US government. At a time when drug policy discussions are opening up around the world, there is an urgent to bring the best of non-ideologically-driven health science, social science and policy analysis to the study of drugs and the potential for policy reform. POLICY ALTERNATIVES IN REAL LIFE: Concrete experiences from many countries that have modified or rejected prohibitionist approaches in their response to drugs can inform discussions of drug policy reform. A number of countries, such as Portugal and the Czech Republic, decriminalised minor drug offenses years ago, with significant savings of money, less incarceration, significant public health benefits, and no significant increase in drug use. Decriminalisation of minor offenses along with scaling up low-threshold HIV prevention services enabled Portugal to control an explosive unsafe injection-linked HIV epidemic and likely enabled the Czech Republic to prevent one from happening. Where formal decriminalisation may not be an immediate possibility, scaling up health services for PWUD can demonstrate the value to society of responding with support rather than punishment to people who commit minor drug infractions. A pioneering OST program in Tanzania is encouraging communities and officials to consider non-criminal responses to heroin injection. In Switzerland and the city of Vancouver, Canada, dramatic improvements in access to comprehensive harm reduction services, including supervised injection sites and heroin-assisted treatment, transformed the health picture for PWUD. Vancouver’s experience also illustrates the importance of meaningful participation of PWUD in decision-making on policies and programmes affecting their communities. CONCLUSIONS AND RECOMMENDATIONS: Policies meant to prohibit or greatly suppress drugs present a paradox. They are portrayed and defended vigorously by many policy-makers as necessary to preserve public health and safety, and yet the evidence suggests they have contributed directly and indirectly to lethal violence, communicable disease transmission, discrimination, forced displacement, unnecessary physical pain, and the undermining of people’s right to health. Some would argue that the threat of drugs to society may justify some level of abrogation of human rights for protection of collective security, as is also foreseen by human rights law in case of emergencies. International human rights standards dictate that in such cases, societies still must choose the least harmful way to address the emergency and that emergency measures must be proportionate and designed specifically to meet transparently defined and realistic goals. The pursuit of drug prohibition meets none of these criteria. Standard public health and scientific approaches that should be part of policy-making on drugs have been rejected in the pursuit of prohibition. The idea of reducing the harm of many kinds of human behavior is central to public policy in the areas of traffic safety, tobacco and alcohol regulation, food safety, safety in sports and recreation, and many other areas of human life where the behavior in question is not prohibited. But explicitly seeking to reduce drug-related harms through policy and programmes and to balance prohibition with harm reduction is regularly resisted in drug control. The persistence of unsafe injection-linked HIV and HCV transmission that could be stopped with proven, cost-effective measures remains one of the great failures of the global responses to these diseases. Drug policy that is dismissive of extensive evidence of its own negative impact and of approaches that could improve health outcomes is bad for all concerned. Countries have failed to recognise and correct the health and human rights harms that pursuit of prohibition and drug suppression have caused and in so doing neglect their legal responsibilities. They readily incarcerate people for minor offenses but then neglect their duty to provide health services in custodial settings. They recognize uncontrolled illegal markets as the consequence of their policies, but they do little to protect people from toxic, adulterated drugs that are inevitable in illegal markets or the violence of organized criminals, often made worse by policing. They waste public resources on policies that do not demonstrably impede the functioning of drug markets, and they miss opportunities to invest public resources wisely in proven health services for people often too frightened to seek services. To move toward the balanced policy that UN member states have called for, we offer the following recommendations: Decriminalisation: Decriminalise minor, non-violent drug offenses – use, possession, and petty sale – and strengthen health and social-sector alternatives to criminal sanctions. Reducing violence and discrimination in policing: Reduce the violence and other harms of drug policing, including phasing out the use of military forces in drug policing, better targeting of policing on the most violent armed criminals, allowing possession of syringes, not targeting harm reduction services to boost arrest totals, and eliminating racial and ethnic discrimination in policing. Reducing harms: Ensure easy access for all who need them to harm reduction services as a part of responding to drugs, recognizing the effectiveness and cost-effectiveness of scaling up and sustaining these services. OST, NSP, supervised injection sites, and access to naloxone – brought to a scale adequate to meet demand – should all figure in health services and should include meaningful participation of PWUD in planning and implementation. Harm reduction services are crucial in prison and pretrial detention and should be scaled up in these settings. The 2016 UNGASS should do better than the UN Commission on Narcotic Drugs (CND) in naming harm reduction explicitly and endorsing its centrality to drug policy. Treatment and care for PWUD: Prioritize PWUD in treatment for HIV, HCV, TB, and ensure that services are adequate to ensure access for all who need care. Ensure availability of humane and scientifically sound treatment for drug dependence, including scaled-up OST in the community as well as in prisons, rejecting compulsory detention and abuse in the name of treatment. Access to controlled medicines: Ensure access to controlled medicines, establishing inter-sectoral national authorities to determine levels of need and giving the World Health Organization (WHO) the resources to assist the International Narcotics Control Board (INCB) in using the best science to determine the level of need for controlled medicines in all countries. Gender-responsive policies: Reduce the negative impact of drug policy and law on women and their families, especially minimizing custodial sentences for women who commit non-violent offenses and developing appropriate health and social support, including gender-appropriate treatment of drug dependence, for those who need it. Crop production: Efforts to address drug crop production must take health into account. Aerial spraying of toxic herbicides should be stopped, and alternative development programmes should be part of integrated development strategies, developed and implemented in meaningful consultation with the people affected. Improve research: There is a need for a more diverse donor base to fund the best new science on drug policy experiences in a non-ideological way that, among other things, interrogates and moves beyond the excessive pathologising of drug use. UN governance of drug control: UN governance of drug policy must be improved, including by respecting WHO’s authority to determine the dangerousness of drugs. Countries should be urged to include high-level health officials in their delegations to CND. Improved representation of health officials in national delegations to CND would, in turn, be a likely result of giving health authorities an important day-to-day role in multi-sectoral national drug policy-making bodies. Better metrics: Health, development, and human rights indicators should be included in metrics to judge success of drug policy; WHO and UNDP should help formulate them. UNDP has already suggested that indicators such as access to treatment, rate of overdose deaths, and access to social welfare programmes for people who use drugs would be useful indicators. All drug policies should also be monitored and evaluated as to their impact on racial and ethnic minorities, women, children and young people, and people living in poverty. Scientific approach to regulated markets: Move gradually toward regulated drug markets and apply the scientific method to their evaluation. While regulated legal drug markets are not politically possible in the short term in some places, the harms of criminal markets and other consequences of prohibition catalogued in this report are likely to lead more countries (and more US states) to move gradually in that direction, a direction we endorse. As those decisions are taken, we urge governments and researchers to apply the scientific method and ensure independent, multidisciplinary and rigorous evaluation of regulated markets to draw lessons and inform improvements in regulatory practices, and to continue evaluating and improving. We urge health professionals in all countries to inform themselves and join debates on drug policy at all levels. True to the stated goals of the international drug control regime, it is possible to have drug policy that contributes to the health and well-being of humankind, but not without bringing to bear the evidence of the health sciences and the voices of health professionals.

AIDS Free World Toronto ON Canada

Center for Public Health and Human Rights Johns Hopkins Bloomberg School of Public Health Baltimore MD USA

Central European University Budapest Hungary

Centro de Investigación y Docencia Económicas Mexico City Mexico

Charles University Prague Czech Republic

Columbia University New York City NY USA

Human Rights Watch Yangon Myanmar

Ministry of Health Lisbon Portugal

RTI International Washington DC USA

Trivandrum Institute of Palliative Sciences Trivandrum India

UN Special Envoy HIV in Eastern Europe and Central Asia Geneva Switzerland

University of Bristol Bristol UK

University of British Columbia Center of Excellence in HIV AIDS Vancouver BC Canada

University of California San Diego San Diego CA USA

University of California San Francisco San Francisco CA USA

University of Malaya Kuala Lumpur Malaysia

University of the Andes Bogotá Colombia

University of Uyo Uyo Nigeria

Warsaw Poland

Yale University New Haven CT USA

Youth Rise Nigeria Lagos Nigeria

Komentář v

Lancet. 2016 Jun 18;387(10037):2505. doi: 10.1016/S0140-6736(16)30796-6. PubMed

Zobrazit více v PubMed

Ban Ki-moon (UN Secretary General) Message on International Day Against Drug Trafficking and Abuse, 26 June 2015. New York: United Nations Information Office; 2015. http://www.unis.unvienna.org/unis/en/pressrels/2015/unissgsm645.html (accessed 15 August 2015)

United Nations General Assembly. Transforming our world: the 2030 agenda for sustainable development. New York: United Nations; 2015.

West Africa Commission on Drugs. Not just in transit: drugs, the state and society in West Africa. Accra: 2014.

United Nations High Commissioner for Human Rights. Study on the impact of the world drug problem on the enjoyment of human rights. Human Rights Council, 30th session. 2015

United Nations General Assembly. Political Declaration of the UN General Assembly Special Session on the World Drug Problem. 1998

United Nations Single Convention on Narcotic Drugs. 1961 as amended by the 1972 Protocol amending the Single Convention on Narcotic Drugs. New York: United Nations; 1961. PubMed

United Nations Office on Drugs and Crime (UNODC) World Drug Report. Vienna: 2015.

McAllister WB. Reflections on a century of international drug control. In: Collins J, editor. Governing the global drug wars. London: London School of Economics; 2012. pp. 10–6.

Collins J. The economics of new global strategy. In: Collins J, editor. Ending the drug wars: Report of the LSE Expert Group on the Economics of Drug Policy. London: London School of Economics; 2014. pp. 8–15.

United Nations International Drug Control Programme. Information sheet no 2 for UN General Assembly Special Session on the World Drug Problem. Vienna: 1998. Key Statistics: Illicit Drug Production, Trafficking and Consumption.

United Nations Office on Drugs and Crime. World drug report. Vienna: 2008.

United Nations Commission on Narcotic Drugs. Joint Ministerial Statement of the 2014 High-Level Review by the Commission on Narcotic Drugs of the implementation by member states of the Political Declaration and Plan of Action on International Cooperation towards an integrated and balanced strategy to counter the world drug problem. 2014

United Nations Development Programme. Addressing the development dimensions of drug policy. New York: 2015.

World Health Organization Executive Board. Public health dimension of the world drug problem including in the context of the Special Session of the United Nations General Assembly on the World Drug Problem, to be held in 2016: Report of the secretariat. 2016. (138th session, doc. EB 138/11).

Organization of American States. The drug problem in the Americas. Washington, D.C.: 2013.

Global Commission on Drug Policy. War on Drugs. 2011

Latin American Commission on Drugs and Democracy. Drugs and democracy: toward a paradigm shift. Rio de Janeiro: 2010.

Global Commission on HIV and the Law. HIV and the law: risks, rights, and health. New York: 2012.

United Nations Office on Drugs and Crime Regional Centre for East Asia and the Pacific. Drug-free ASEAN 2015: status and recommendations. Bangkok: 2008.

Fawthrop T. ‘Drug free’ ASEAN by 2015? Diplomat. 2015 Aug 8; http://thediplomat.com/2015/08/drug-free-asean-by-2015/ (accessed 15 August 2015)

Centers for Disease Control and Prevention. CDC Vital Signs: Today’s heroin epidemic. 2015 http://www.cdc.gov/vitalsigns/heroin/ (accessed 16 August 2015)

King NB, Fraser V, Boikos C, Richardson R, Harper S. Determinants of increased opioid-related mortality in the United States and Canada, 1990–2013: a systematic review. Am J Public Health. 2014;104:e32–e42. PubMed PMC

Canadian HIV/AIDS Legal Network CDPC. Drug policy and overdose prevention and response. Toronto and Vancouver: 2015.

Zezima K. Presidential candidates are actually talking about America’s heroin issue. Washington Post. 2015 Jun 3; https://www.washingtonpost.com/politics/drug-epidemic-shapes-messages-on-the-presidential-campaign-trail/2015/06/03/2f63761c-00d0-11e5-805c-c3f407e5a9e9_story.html (accessed 4 Sept 2015)

Case A, Deaton A. Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century. Proc Natl Acad Sci USA. 2015;112:15078–83. PubMed PMC

Seelye KQ. In heroin crisis, white families seek gentler war on drugs. New York Times. 2015 Oct 30; http://www.nytimes.com/2015/10/31/us/heroin-war-on-drugs-parents.html?_r=0 (accessed 16 January 2016)

Pardo B. Cannabis policy reforms in the Americas: a comparative analysis of Colorado, Washington, and Uruguay. Int J Drug Policy. 2014;25:727–35. PubMed

Ingold J. Marijuana case filings plummet in Colorado following legalization. Denver Post. 2014

World Health Organization. World Report on Violence and Health. Geneva: 2002.

World Health Organization, UN Office on Drugs and Crime, UN Development Programme. Global status report on violence prevention 2014. Geneva: 2014.

Collaborators in the Global Burden of Disease Study. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117–71. PubMed PMC

Osorio J. The contagion of drug violence: spatiotemporal dynamics of the Mexican war on drugs. J Conflict Resolution. 2015;59:1403–32.

United Nations Office on Drugs and Crime (UNODC) 23rd session, Commission on Crime Prevention and Criminal Justice. Vienna: 2014. World crime trends and emerging issues and responses in the field of crime prevention and criminal justice.

United Nations Office on Drugs and Crime (UNODC) Transnational organized crime in Central America and the Caribbean: a threat assessment. Vienna: 2012.

Center for Gender and Refugee Studies. A treacherous journey: child migrants navigating the US immigration system. Hastings College of Law; San Francisco: 2014.

Mares A. The Rise of femicide and women in drug trafficking. Washington, DC: Council on Hemispheric Affairs; 2011.

Fox E. How the drug trade fuels femicide in Central America. InsightCrime. 2012 Jul 19; http://www.insightcrime.org/news-analysis/how-the-drug-trade-fuels-femicide-in-central-america (accessed 19 September 2015)

Cantor DJ. The new wave: forced displacement caused by organized crime in Central America and Mexico. Refugee Surv Q. 2014;33:34–68.

Atuesta Becerra L. Addressing the costs of prohibition: Internally displaced populations in Colombia and Mexico. In: Collins J, editor. Ending the Drug Wars: Report of the LSE Expert Group on the Economics of Drug Policy. London School of Economics; 2014. pp. 49–54.

Norwegian Refugee Council. Displacement in the wake of violence in Central America: Humanitarian implications and protection needs. Oslo: 2014.

Robinson LK. Arrived: the crisis of unaccompanied children at our southern border. Pediatrics. 2015;135:205–7. PubMed

Canudas-Romo V, García-Guerrero VM, Echarri-Cánovas CJ. The stagnation of the Mexican male life expectancy in the first decade of the 21st century: the impact of homicides and diabetes mellitus. J Epidemiol Comm Health. 2015;69:28–34. PubMed

Gonzalez-Perez GJ, Vega-Lopez MG, Cabrera-Pivaral CE. Impact of homicide on male life expectancy in Mexico. Pan Am J Public Health. 2012;32:335–42. PubMed

Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335–51. PubMed

Mexican National Institute of Statistics and Geography (INEGI) Administrative registers of death. 2014 http://www.inegi.org.mx/est/contenidos/proyectos/registros/vitales/mortalidad/default.aspx (accessed 17 August 2015)

Heinle K, Molzahn C, Shirk DA. Drug violence in Mexico; data analysis through 2014. University of San Diego: Justice in Mexico Project; 2015.

Espinosa V, Rubin DB. Did the military interventions in the Mexican drug war increase violence? Am Statistician. 2015;69:17–27.

Perez Correa C, Azeola E. Resultados de la primera encuesta realizada en los Centros Federales de Readaptación Social. Mexico City: CIDE; 2012.

Madrazo Lajous A. The constitutional costs of the ‘war on drugs’. In: Collins J, editor. Ending the war on drugs: Report of the LSE Expert Group on the Economics of Drug Policy. London School of Economics; 2014. pp. 55–60.

Mejia D, Restrepo P. Why is strict prohibition collapsing? In: Collins J, editor. Ending the war on drugs: Report of the LSE Expert Group on the Economics of Drug Policy. London School of Economics; 2014. pp. 26–32.

Legalising marijuana: the view from Mexico. Economist. 2012 Nov 2;

Grillo I. Legalization of marijuana has hit Mexican cartels’ cross-border trade. Time. 2015 Apr 8;

Mejia D, Restrepo P. Bushes and bullets: Illegal cocaine markets and violence in Colombia. Bogotá: Universidad de los Andes; 2013. (Documento CEDE # 53).

United Nations General Assembly. Resolution adopted by the General Assembly on 20 December 2012: international cooperation against the world drug problem. 2012. (UN doc. A/RES/67/193, 23 April 2013).

Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010;376:285–301. PubMed

Degenhardt L, Mathers BM, Wirtz AL, et al. What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010–2012? A review of the six highest burden countries. Int J Drug Policy. 2014;25:53–60. PubMed

UNAIDS. The gap report. Geneva: 2014.

UNAIDS. How AIDS changed everything. Geneva: 2015.

World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva: 2014. PubMed

Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol. 2008;168:1099–109. PubMed PMC

Vickerman P, Martin NK, Roy A, et al. Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission? Drug Alcohol Dep. 2013;132:172–81. PubMed

World Health Organization, United Nations Office on Drugs and Crime, UN Joint Programme on HIV/AIDS. Technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users – 2012 revision. Geneva: 2012.

Wodak A, Cooney A. Effectiveness of sterile needle and syringe programming in reducing HIV/AIDS among injecting drug users. Geneva: World Health Organization; 2004.

Aspinall EJ, Nambiar D, Goldberg DJ, et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol. 2014;43:235–48. PubMed

MacArthur GJ, van Velzen E, Palmateer N, et al. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy. 2014;25:34–52. PubMed

Turner KM, Hutchinson S, Vickerman P, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction. 2011;106:1978–88. PubMed

MacArthur GJ, Minozzi S, Martin N, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ (Clinical Research Ed) 2012;345:e5945. PubMed PMC

Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med. 2014;174:1974–81. PubMed PMC

Nolan S, Lima VD, Fairbairn N, et al. The impact of methadone maintenance therapy on heptatis C incidence among illicit drug users. Addiction. 2014;109:2053–9. PubMed PMC

White B, Dore GJ, Lloyd AR, Rawlinson WD, Maher L. Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITS-c study. The Medical journal of Australia. 2014;201:326–9. PubMed

Palmateer NE, Taylor A, Goldberg DJ, et al. Rapid decline in HCV incidence among people who 1inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions. PLoS One. 2014;9(8):e104515. PubMed PMC

van Den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction. 2007;102:1454–62. PubMed PMC

Vickerman P, Martin N, Turner K, Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction. 2012;107:1984–95. PubMed

Guise A, Kazatchkine M, Rhodes T, Strathdee SA. Successful methadone delivery in East Africa and its global implications. Clin Infect Dis. 2014;59:743–44. PubMed

European Monitoring Centre on Drugs and Drug Addiction (EMCDDA) European drug report 2015: trends and development. Lisbon: 2015.

Harm Reduction International. Global state of harm reduction. London: 2014.

Vagenas P, Azbel L, Polonsky M, et al. A review of medical and substance use co-morbidities in Central Asian prisons: implications for HIV prevention and treatment. Drug Alcohol Dep. 2013;1323(Suppl 1):S25–31. PubMed PMC

Hoang TV, Ha TT, Hoang TM, Nhu NT, Quoc NC, Tam N, et al. Impact of a methadone maintenance therapy pilot in Vietnam and its role in a scaled-up response. Harm Reduct J. 2015;12:39. PubMed PMC

Vickerman P, Platt L, Jolley E, Rhodes T, Kazatchkine MD, Latypov A. Controlling HIV among people who inject drugs in Eastern Europe and Central Asia: Insights from modelling. Int J Drug Policy. 2014;25:1163–73. PubMed

Strathdee SA, Hallett TB, Bobrova N, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet. 2010;376:268–84. PubMed PMC

Wolfe D. Paradoxes in antiretroviral treatment for injecting drug users: access, adherence and structural barriers in Asia and the former Soviet Union. Int J Drug Policy. 2007;18:246–54. PubMed

Kerr T, Marshall BD, Milloy MJ, et al. Patterns of heroin and cocaine injection and plasma HIV-1 RNA suppression among a long-term cohort of injection drug users. Drug Alcohol Dep. 2012;124:108–12. PubMed PMC

Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010;376:355–66. PubMed

Reddon H, Milloy MJ, Simo A, Montaner J, Wood E, Kerr T. Methadone maintenance therapy decreases the rate of antiretroviral therapy discontinuation among HIV-positive illicit drug users. AIDS Behav. 2014;18:740–6. PubMed PMC

Bach P, Wood E, Dong H, et al. Association of patterns of methadone use with antiretroviral therapy discontinuation: a prospective cohort study. BMC Infect Dis. 2015;15:537. PubMed PMC

Lappalainen L, Nolan S, Dobrer S, et al. Dose-response relationship between methadone dose and adherence to antiretroviral therapy among HIV-positive people who use illicit opioids. Addiction. 2015;110(8):1330–9. PubMed PMC

Lin C, Cao X, Li L. Integrating antiretroviral therapy in methadone maintenance therapy clinics: service provider perceptions. Int J Drug Policy. 2014;25:1066–70. PubMed PMC

Bachireddy C, Soule MC, Izenberg JM, Dvoryak S, Dumchev K, Altice FL. Integration of health services improves multiple healthcare outcomes among HIV-infected people who inject drugs in Ukraine. Drug Alcohol Dep. 2014;134:106–14. PubMed PMC

Latypov A, Grund J-P, El-Bassel N, Platt L, Stöver H, Strathdee S. Illicit drugs in Central Asia: What we know, what we don’t know, and what we need to know. Int J Drug Policy. 2014;25:1155–62. PubMed

Momenghalibaf A. Hepatitis C treatment: Price, profits, and barriers to access. New York: Open Society Foundations; 2013.

Ford N, Singh K, Cooke GS, et al. Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis. 2012;54:1465–72. PubMed

Grebely J, Haire B, Taylor LE, et al. Excluding people who use drugs or alcohol from access to hepatitis C treatments – Is this fair, given the available data? J Hepatol. 2015;63:779–82. PubMed PMC

Aspinall EJ, Corson S, Doyle JS, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis. 2013;57(Suppl 2):S80–9. PubMed

Martin NK, Vickerman P, Grebely J, et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatol. 2013;58:1598–609. PubMed PMC

Martin NK, Vickerman P, Miners A, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatol. 2012;55:49–57. PubMed

Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis. 2013;57(Suppl 2):S39–45. PubMed PMC

Wolfe D, Luhmann N, Harris M, et al. Human rights and access to hepatitis C treatment for people who inject drugs. Int J Drug Policy. 2015;26:1072–80. PubMed

World Health Organization U, UN Office on Drugs and Crime et al. HIV and young men who have sex with men: Technical brief. Geneva: WHO; 2015.

Shoptaw S, Reback CJ. Methamphetamine use and infectious disease-related behaviors in men who have sex with men: implications for interventions. Addiction. 2007;102:130–5. PubMed

Daskalopoulou M, Rodger A, Phillips AN, et al. Recreational drug use, polydrug use, and sexual behaviour in HIV-diagnosed men who have sex with men in the UK: results from the cross-sectional ASTRA study. Lancet HIV. 2014;1(1):e22–31. PubMed

Nguyen TV, Van Khuu N, Nguyen PD, et al. Sociodemographic factors, sexual behaviors, and alcohol and recreational drug use associated with HIV among men who have sex with men in Southern Vietnam. AIDS Behav. 2016 epub ahead of print. PubMed PMC

Melendez-Torres GJ, Bourne A. Illicit drug use and its association with sexual risk behaviour among MSM: more questions than answers? Curr Opin Infect Dis. 2016;29:58–63. PubMed

Milloy MJ, Wood E. Emerging role of supervised injecting facilities in human immunodeficiency virus prevention. Addiction. 2009;104:620–1. PubMed

Pinkerton SD. How many HIV infections are prevented by Vancouver Canada’s supervised injection facility? Int J Drug Policy. 2011;22:179–83. PubMed

Coffin PO, Rowe C, Santos GM. Novel interventions to prevent HIV and HCV among persons who inject drugs. Curr HIV/AIDS Rep. 2015;12:145–63. PubMed

Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083–90. PubMed

Atun R, Kazatchkine M. The Global Fund’s leadership on harm reduction: 2002–2009. Int J Drug Policy. 2010;21:103–6. PubMed

Bridge J, Hunter BM, Albers E, et al. The Global Fund to Fight AIDS, Tuberculosis and Malaria’s investments in harm reduction through the rounds-based funding model (2002–2014) Int J Drug Policy. 2016;27:132–7. PubMed

Panitchpakdi P. The imbalance between government and civil society in Global Fund processes: A View from Thailand. Glob Fund Obs. 2006;(65)

Cook C, Bridge J, McLean S, Phelan M, Barrett D. The funding crisis for harm reduction: donor retreat, government neglect and the way forward. London: Harm Reduction International, International HIV/AIDS Alliance and International Drug Policy Consortium; 2014.

Eurasian Harm Reduction Network. Alert announcement: Serbia is losing harm reduction! (online) 2015 http://www.harm-reduction.org/blog/alert-announcement-serbia-losing-harm-reduction (accessed 24 Sept 2015)

Harm Reduction International. 10 by 20: a call to redirect resources from the war on drugs to harm reduction – 10% by 2020. London: 2015.

Niculescu I, Paraschiv S, Paraskevis D, et al. Recent HIV-1 Outbreak Among Intravenous Drug Users in Romania: Evidence for Cocirculation of CRF14_BG and Subtype F1 Strains. AIDS Res Human Retrovir. 2014;31:488–95. PubMed PMC

Botescu A, Abagiu A, Mardarescu M, Ursan M. HIV/AIDS among injecting drug users in Romania: Report of a recent outbreak and initial response policies. European Monitoring Centre on Drugs and Drug Addiction (EMCDDA); Lisbon: 2012.

Oprea C. Victor Babes Hospital, Bucharest, personal communication. 2015

Paraskevis D, Nikolopoulos G, Fotiou A, et al. Economic Recession and Emergence of an HIV-1 Outbreak among Drug Injectors in Athens Metropolitan Area: A Longitudinal Study. PLoS ONE. 2013;8(11):e78941. PubMed PMC

Sarafis P, Tsounis A. Debt burden of Greece and HIV among injecting drug users. Lancet Infect Dis. 2014;14:180–1. PubMed

European Monitoring Centre on Drugs and Drug Addiction (EMCDDA) Harm Reduction Overview for Greece (online) http://www.emcdda.europa.eu/country-data/harm-reduction/Greece (accessed 24 August 2015)

Strathdee SA, Beyrer C. Threading the needle — how to stop the HIV outbreak in rural Indiana. N Engl J Med. 2015;373:397–9. PubMed

Ungar L. Funding ban on needle exchanges effectively lifted. 2016 http://www.usatoday.com/story/news/nation/2016/01/07/funding-ban-needle-exchanges-effectively-lifted/78420894/ (accessed 18 January 2016)

Conrad C, Bradley HM, Broz D, et al. Community outbreak of HIV Infection linked to injection drug use of oxymorphone–Indiana, 2015. MMWR CDC Surveillance Summaries. 2015;64:443–4. PubMed PMC

Government of Australia National Centre in HIV Epidemiology and Clinical Research. Return on investment 2: evaluating the costeffectiveness of needle and syringe programs in Australia. Canberra: 2009.

Naning H, Kerr C, Kamarulzaman A, et al. Return on investment and cost-effectiveness of harm reduction program in Malaysia. Washington, DC: World Bank; 2014.

Wilson DP, Donald B, Shattock AJ, Wilson D, Fraser-Hurt N. The cost-effectiveness of harm reduction. Int J Drug Policy. 2015;26(Suppl 1):S5–11. PubMed

Brooner R, Kidorf M, King V, Beilenson P, Svikis D, Vlahov D. Drug abuse treatment success among needle exchange participants. Public Health Rep. 1998;113(Suppl 1):129–39. PubMed PMC

World Health Organization, United Nations Office on Drugs and Crime, UN Joint Programme on HIV/AIDS. Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention. Geneva: 2004.

Burris S. Law in a social determinants strategy: a public health law research perspective. Public Health Rep. 2011;126(Suppl 3):22–7. PubMed PMC

Lunze K, Raj A, Cheng DM, et al. Punitive policing and associated substance use risks among HIV-positive people in Russia who inject drugs. J Int AIDS Soc. 2014;17(1):19043. PubMed PMC

Government of the Russian Federation. HIV infection in the Russian Federation. 2014 http://www.hivrussia.ru/files/spravkaHIV (accessed 20 Sept 2015)

Canadian HIV AIDS Legal Network. Module 2: treatment for drug dependence. Toronto: 2006. egislating for health and human rights – model law on drug use and HIV/AIDS.

Tanguay P, Ngamee V. CHAMPION-IDU: Innovations, best practices, lessons learned. Bangkok: Population Services International; 2015.

Sarang A, Rhodes T, Sheon N. Systemic barriers accessing HIV treatment among people who inject drugs in Russia: a qualitative study. Health Policy Planning. 2013;28:681–91. PubMed PMC

Ti L, Hayashi K, Kaplan K, Suwannawong P, Wood E, Kerr T. Contextual factors associated with rushed injecting among people who inject drugs in Thailand. Prevention Sci. 2015;16:313–20. PubMed

Ahmed T, Long TN, Huong PT, Stewart DE. Drug injecting and HIV risk among injecting drug users in Hai Phong, Vietnam: a qualitative analysis. BMC Public Health. 2015;15:32. PubMed PMC

Beletsky L, Heller D, Jenness SM, Neaigus A, Gelpi-Acosta C, Hagan H. Syringe access, syringe sharing, and police encounters among people who inject drugs in New York City: a community-level perspective. Int J Drug Policy. 2014;25(1):105–11. PubMed PMC

VOCAL-NY Users Union. Beyond methadone: improving health and empowering patients in opioid treatment programs. New York: 2015.

Open Society Foundations. To protect and serve: How police, sex workers, and people who use drugs are joining forces to improve health and human rights. New York: 2013.

Wood E, Kerr T, Small W, Jones J, Schechter MT, Tyndall MW. The Impact of a Police Presence on Access to Needle Exchange Programs. J Acquir Immune Defic Syndr. 2003;34:116–7. PubMed

Maher L, Dixon D. Cost of Crackdowns: Policing Cabramatta’s Herion Market, The. Curr Issues Crim Just. 2001;13:5.

Kerr T, Small W, Wood E. The public health and social impacts of drug market enforcement: A review of the evidence. Int J Drug Policy. 2005;16:210–20.

Bazazi AR, Zelenev A, Fu JJ, Yee I, Kamarulzaman A, Altice FL. High prevalence of non-fatal overdose among people who inject drugs in Malaysia: Correlates of overdose and implications for overdose prevention from a cross-sectional study. Int J Drug Policy. 2015;26:675–81. PubMed PMC

World Health Organization. Global tuberculosis report. Geneva: 2014.

World Health Organization, United Nations Office on Drugs and Crime, UN Joint Programme on HIV/AIDS. Policy guidelines for collaborative TB and HIV services for injecting and other drug users: an integrated approach (Evidence for Action Technical Papers. Geneva: 2008. PubMed

Getahun H, Gunneberg C, Sculier D, Verster A, Raviglione M. Tuberculosis and HIV in people who inject drugs: evidence for action for tuberculosis, HIV, prison and harm reduction services. Curr Opin HIV AIDS. 2012;7(4):345–53. PubMed

Deiss RG, Rodwell TC, Garfein RS. Tuberculosis and Drug Use: Review and Update. Clin Infect Dis. 2009;48(1) doi: 10.1086/594126. PubMed DOI PMC

World Health Organization. Drug-resistant tuberculosis: frequently asked questions. Geneva: 2012.

Schluger NW, El-Bassel N, Hermosilla S, et al. Tuberculosis, drug use and HIV infection in Central Asia: an urgent need for attention. Drug Alcohol Dep. 2013;132(Suppl 1):S32–6. PubMed

World Health Organization. Policy guidelines for integrating collaborative TB and HIV services within the comprehensive package of harm reduction for people who inject drugs. Geneva: 2015.

Keshavjee S, Sweeney C, Yedilbayev A, Taran D, Solovyova A, Gelmanova I. The Sputnik Initiative: Patient-centered accompaniment for tuberculosis in Russia. Partners in Health Reports. 2014;1(2)

Al-Darraji HA, Wong KC, Yeow DG, et al. Tuberculosis screening in a novel substance abuse treatment center in Malaysia: implications for a comprehensive approach for integrated care. J Subst Abuse Treat. 2014;46(2):144–9. PubMed PMC

Getahun H, Baddeley A, Raviglione M. Managing tuberculosis in people who use and inject illicit drugs. Bull World Health Organ. 2013;91(2):154–6. PubMed PMC

World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. Geneva: 2014. PubMed

Rosmarin A, Eastwood N. A quiet revolution: drug decriminalisation policies in practice across the globe. London: Release 2012.

United Kingdom Home Office. International comparators. London: 2014.

DeBeck K, Kerr T, Li K, Milloy MJ, Montaner J, Wood E. Incarceration and drug use patterns among a cohort of injection drug users. Addiction. 2009;104:69–76. PubMed PMC

Reinarman C, Cohen PD, Kaal HL. The limited relevance of drug policy: cannabis in Amsterdam and in San Francisco. Am J Public Health. 2004;94:836–42. PubMed PMC

Uprimny R, Esther D, Parra J. Addicted to punishment: The disproportionality of drug laws in Latin America. Colectivo de Estudios de Drogas y Derecho (CEDD); Mexico City: 2013.

Penal Reform International. Global prison trends 2015. London: 2015.

Giacomello C. How the drug trade criminalizes women disproportionately. NACLA Report on the Americas. 2014;47:38–41.

Organization of American States Inter-American Commission of Women. Women and drugs in the Americas: A policy working paper. Washington, D.C.: 2014.

Carson A. Prisoners in 2014. Washington, D.C.: Bureau of Justice Statistics (NCJ 248955); 2015.

O’Hara M. International drug crime measures ‘lead to executions’. The Guardian. 2010

Gallahue P, Gunawan R, Rahman F, El Mufti K, Din NU, Felten R. The death penalty for drug offences: global overview 2012. London: International Harm Reduction Association; 2012.

United Nations. Commentary on the Single Convention on Narcotic Drugs 1961, E.73.XI.1. 1971:449–50.

Lines R, Barrett D, Gallahue P. The death penalty for drug offenses: Asian values or treaty influence? OpinioJuris. 2015 May 21; http://opiniojuris.org/2015/05/21/guest-post-the-death-penalty-for-drug-offences-asian-values-or-drug-treaty-influence/ (accessed 23 Sept 2015)

Grover A. (Human Rights UN General Assembly, 65th Session. UN doc. A/65/255).Report of the Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health. 2010

Phipps C. Who were the eight people executed by Indonesia? Guardian. 2015 Apr 29; At: http://www.theguardian.com/world/2015/apr/29/bali-nine-who-are-the-nine-people-being-executed-by-indonesia (accessed 14 Oct 2015)

Gallahue P. Drugs and the death penalty. New York: Open Society Foundations; 2015.

Walmsley R. World prison population list. 10th. Essex: International Centre for Prison Studies; 2013.

Snyder HN, Mulako-Wangota J. Arrests in the United States, 1980–2012. Bureau of Justice Statistics; Washington, D.C.: 2014.

Sentencing Project. Facts about prisons and people in prisons. Washington, DC: 2014. http://sentencingproject.org/doc/publications/inc_Facts%20About%20Prisons.pdf (accessed 2 Oct 2015)

Sentencing Project. Trends in U.S. corrections. Washington, D.C.: 2014. http://sentencingproject.org/doc/publications/inc_Trends_in_Corrections_Fact_sheet.pdf (accessed 2 October 2015)

Carson A. Prisoners in 2013. Washington, D.C.: U.S. Bureau of Justice Statistcs (NCJ 247282); 2014.

Levine HG, Siegel L. Marijuana madness: The scandal of New York City’s racist marijuana possession arrests. In: Eterno JA, editor. The New York City Police Department: the impact of its policies and practices. New York: CRC Press; 2015. pp. 117–61.

Snyder HN. Arrests in the United States, 1990–2010. Bureau of Justice Statistics; Washington, D.C.: 2012.

Widman L, Noar SM, Golin CE, Willoughby JF, Crosby R. Incarceration and unstable housing interact to predict sexual risk behaviours among African American STD clinic patients. Int J STD & AIDS. 2014;25(5):348–54. PubMed PMC

Adimora AA, Schoenbach VJ, Martinson FE, Donaldson KH, Stancil TR, Fullilove RE. Concurrent partnerships among rural African Americans with recently reported heterosexually transmitted HIV infection. J Acquir Immune Defic Syndr. 2003;34:423–9. PubMed

Johnson RC, Raphael S. The effects of male incarceration dynamics on acquired immune deficiency syndrome infection rates among African American women and men. J Law Econ. 2009;52(2):251–93.

Jeffries S, Stenning P. Sentencing, aboriginal offenders: law, policy, and practice in three Countries. Can J Criminol Criminal Justice. 2014;56:447–94.

Statistics Canada. Prison Statistics 2013–14. 2014 http://www.statcan.gc.ca/pub/85-002-x/2015001/article/14163-eng.htm#a8 (accessed 4 October 2015)

Minority Rights Group International. World directory of minorities and indigenous peoples: Brazil – Afro-Brazilians. London: 2014.

Horwitz S. Justice Department set to free 6,000 prisoners, largest one-time release. Washington Post. 2015 Oct 6; https://www.washingtonpost.com/world/national-security/justice-department-about-to-free-6000-prisoners-largest-one-time-release/2015/10/06/961f4c9a-6ba2-11e5-aa5b-f78a98956699_story.html (accessed 10 October 2015)

United Nations Economic and Social Council. United Nations Rules for the Treatment of Women Prisoners and Non-custodial Measures for Women Offenders (the Bangkok Rules) New York: 2010. Doc. 2010/16.

Iakobishvili E. Cause for Alarm: The Incarceration of Women for Drug offences in Europe and Central Asia, and the need for legislative and Sentencing reform. London: International Harm Reduction Association; 2012.

UNODC UN Women World Health Organization International Network of People Who Use Drugs. Women who inject drugs and HIV: addressing specific needs. Vienna: 2015.

Green KM, Ensminger ME, Robertson JA, Juon HS. Impact of adult sons’ incarceration on African American mothers’ psychological distress. J Marriage Family. 2006;68:430–41. PubMed PMC

Lee H, Wildeman C. Things fall apart: Health consequences of mass imprisonment for African American women. Rev Black Political Econ. 2013;40:39–52.

Lee H, Wildeman C, Wang EA, Matusko N, Jackson JS. A heavy burden: the cardiovascular health consequences of having a family member incarcerated. Am J Public Health. 2014;104:421–7. PubMed PMC

Turney K. Stress proliferation across generations? Examining the relationship between parental incarceration and childhood health. J Health Soc Behav. 2014;55:302–19. PubMed

Wakefield S, Wildeman C. Children of the prison boom: Mass incarceration and the future of American inequality. Oxford University Press; 2013.

Wildeman C, Lee H, Comfort M. A new vulnerable population? The health of female partners of men recently released from prison. Women’s Health Issues. 2013;23:e335–e40. PubMed PMC

Wildeman C, Muller C. Mass imprisonment and inequality in health and family life. Ann Rev Law Social Sci. 2012;8:11–30.

Wildeman C, Schnittker J, Turney K. Despair by association? The mental health of mothers with children by recently incarcerated fathers. Am Sociolog Rev. 2012;77:216–43.

Christian J. Riding the bus barriers to prison visitation and family management strategies. J Contemporary Criminal Justice. 2005;21:31–48.

Codd H. In the shadow of prison: Families, imprisonment and criminal justice. Willan; 2013.

Comfort M. Punishment beyond the legal offender. Annu Rev Law Soc Sci. 2007;3:271–96.

Mannelli P. The burden of caring: drug users and their families. Indian J Medical Res. 2013;137:636–8. PubMed PMC

Comfort M. Doing time together: Love and family in the shadow of the prison. University of Chicago Press; 2009.

Richie BE. The social impact of mass incarceration on women. In: Mauer M, Chesney-Lind M, editors. Invisible punishment: The collateral consequences of mass imprisonment. New York: New Press; 2002. pp. 136–49.

Girshick LB. Soledad women: Wives of prisoners speak out. Westport, CT (USA): Greenwood Publishing Group; 1996.

Comfort M. “A twenty hour a day job”: The repercussive effects of frequent low-level criminal justice involvement on family life. Ann Am Acad Pol Soc Sci. In press. PubMed PMC

Dolan K, Moazen B, Noori A, Rahimzadeh S, Farzadfar F, Hariga F. People who inject drugs in prison: HIV prevalence, transmission and prevention. Int J Drug Policy. 2015;26(Suppl 1):S12–5. PubMed

Culbert GJ, Waluyo A, Iriyanti M, Muchransyah AP, Kamarulzaman A, Altice FL. Within-prison drug injection among HIV-infected male prisoners in Indonesia: a highly constrained choice. Drug Alcohol Dep. 2015;149:71–9. PubMed PMC

Carpentier C, Royuela L, Noor A, Hedrich D. Ten years of monitoring illicit drug use in prison populations in Europe: issues and challenges. Howard J Criminal Justice. 2012;51:37–66.

Jurgens R, Ball A, Verster A. Interventions to reduce HIV transmission related to injecting drug use in prison. Lancet Infect Dis. 2009;9:57–66. PubMed

United Nations Office on Drugs and Crime (UNODC), UNAIDS, World Bank. HIV in prisons: Sub-Saharan Africa – opportunities for action. Vienna: 2007.

Hagan H. The relevance of attributable risk measures to HIV prevention planning. Aids. 2003;17(6):911–3. PubMed

Larney S, Kopinski H, Beckwith CG, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatol. 2013;58(4):1215–24. PubMed PMC

Treloar C, McCredie L, Lloyd AR. Acquiring hepatitis C in prison: the social organisation of injecting risk. Harm Reduct J. 2015;12:10. PubMed PMC

Bretana NA, Boelen L, Bull R, et al. Transmission of Hepatitis C Virus among prisoners, Australia, 2005–2012. Emerg Infect Dis. 2015;21:765–74. PubMed PMC

Bocai A, Iliuta C, Ursan M, Corciova M. HIV, HBV and HCV behavioral surveillance survey among injecting drug users in Bucharest, Romania. United Nations Office on Drugs and Crime; 2010.

Grau LE, White E, Niccolai LM, et al. HIV disclosure, condom use, and awareness of HIV infection among HIV-positive, heterosexual drug injectors in St. Petersburg, Russian Federation. AIDS Behav. 2011;15:45–57. PubMed PMC

Hope VD, Hickman M, Ngui SL, et al. Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots. J Viral Hepat. 2011;18:262–70. PubMed

Li L, Assanangkornchai S, Duo L, McNeil E, Li J. Risk behaviors, prevalence of HIV and hepatitis C virus infection and population size of current injection drug users in a China-Myanmar border city: results from a Respondent-Driven Sampling Survey in 2012. PLoS One. 2014;9(9):e106899. PubMed PMC

Butler T, Boonwaat L, Hailstone S, et al. The 2004 Australian prison entrants’ blood-borne virus and risk behaviour survey. Aust N Z J Public Health. 2007;31:44–50. PubMed

Hickman M, Hope V, Brady T, et al. Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. J Viral Hepat. 2007;14:645–52. PubMed

Kheirandish P, SeyedAlinaghi S, Jahani M, et al. Prevalence and correlates of hepatitis C infection among male injection drug users in detention, Tehran, Iran. J Urban Health. 2009;86:902–8. PubMed PMC

Oliveira Mde L, Bastos FI, Telles PR, et al. Epidemiological and genetic analyses of Hepatitis C virus transmission among young/short- and long-term injecting drug users from Rio de Janeiro, Brazil. J Clin Virol. 2009;44:200–6. PubMed

Wood E, Kerr T, Stoltz J, et al. Prevalence and correlates of hepatitis C infection among users of North America’s first medically supervised safer injection facility. Public Health. 2005;119:1111–5. PubMed

Allen EJ, Palmateer NE, Hutchinson SJ, Cameron S, Goldberg DJ, Taylor A. Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland. Int J Drug Policy. 2012;23:346–52. PubMed

Cepeda JA, Niccolai LM, Lyubimova A, Kershaw T, Levina O, Heimer R. High-risk behaviors after release from incarceration among people who inject drugs in St. Petersburg, Russia. Drug Alcohol Dep. 2015;147:196–202. PubMed PMC

Milloy MJ, Wood E, Small W, et al. Incarceration experiences in a cohort of active injection drug users. Drug Alcohol Rev. 2008;27:693–9. PubMed

Milloy MJ, Buxton J, Wood E, Li K, Montaner JS, Kerr T. Elevated HIV risk behaviour among recently incarcerated injection drug users in a Canadian setting: a longitudinal analysis. BMC Public Health. 2009;9:156. PubMed PMC

Wood E, Li K, Small W, Montaner JS, Schechter MT, Kerr T. Recent incarceration independently associated with syringe sharing by injection drug users. Public Health Rep. 2005;120(2):150–6. PubMed PMC

Stone J, Martin NK, Hickman M. Incarceration of people who inject drugs: modelling its role in HCV transmission and the impact of scaled-up HCV treatment. Submitted.

Martin NK, Vickerman P, Brew I, et al. Is increased HCV case-finding combined with current or 8–12 week interferon-free DAA therapy cost-effective in UK prisons? A prevention benefit analysis. Hepatol. 2016 In press. PubMed PMC

Taylor A, Munro A, Allen E, et al. Low incidence of hepatitis C virus among prisoners in Scotland. Addiction. 2013;108:1296–304. PubMed

Dolan K, Teutsch S, Scheuer N, et al. Incidence and risk for acute hepatitis C infection during imprisonment in Australia. Eur J Epidemiol. 2010;25:143–8. PubMed

Luciani F, Bretana NA, Teutsch S, et al. A prospective study of hepatitis C incidence in Australian prisoners. Addiction. 2014;109:1695–706. PubMed

Buavirat A, Page-Shafer K, van Griensven GJ, et al. Risk of prevalent HIV infection associated with incarceration among injecting drug users in Bangkok, Thailand: case-control study. BMJ (Clinical research ed) 2003;326:308. PubMed PMC

Hayashi K, Ti L, Csete J, et al. Reports of police beating and associated harms among people who inject drugs in Bangkok, Thailand: a serial cross-sectional study. BMC Public Health. 2013;13:733. PubMed PMC

Biadglegne F, Rodloff AC, Sack U. Review of the prevalence and drug resistance of tuberculosis in prisons: a hidden epidemic. Epidemiol Infect. 2015;143(5):887–900. PubMed PMC

Stuckler D, Basu S, McKee M, King L. Mass incarceration can explain population increases in TB and multidrug-resistant TB in European and central Asian countries. Proc Natl Acad Sci USA. 2008;105(36):13280–5. PubMed PMC

World Health Organization – Europe, UNODC. A policy brief on the organization of prison health. Copenhagen: 2013. Good governance for prison health in the 21st century.

European Centre for Disease Prevention and Control. Thematic report: prisoners – Monitoring implementation of the Dublin Declaration on Partnership to fight HIV/AIDS in Europe and Central Asia: 2012 progress report. Stockholm: 2013.

UNAIDS (Joint United Nations Programme on HIV/AIDS) Country report – Ukraine (online) http://www.unaids.org/en/regionscountries/countries/ukraine/. (accessed 26 August 2015)

Russian Federation. Statistics of the federal pentitentiary system (online) http://xn–h1akkl.xn–p1ai/statistics/ (accessed 4 September 2015)

United Nations General Assembly. Basic principles for the treatment of prisoners. UN doc. A/RES/45/111, 14 December 1990.

United Nations Office on Drugs and Crime (UNODC), World Health Organizations, UNAIDS, UN Development Programme, International Labour Organization. Policy brief: HIV prevention, treatment and care in prisons and other closed settings: a comprehensive package of interventions. Vienna: 2013.

European Monitoring Centre on Drugs and Drug Addiction (EMCDDA) Prisons and drugs in Europe: the problem and responses. Lisbon: 2012.

Kopak AM. Breaking the addictive cycle of the system: improving US criminal justice practices to address substance use disorders. Int J Prison Health. 2015;11:4–16. PubMed

Martin NK, Vickerman P, Dore GJ, Hickman M. The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Curr Opin HIV AIDS. 2015;10:374–80. PubMed PMC

Spaulding AS, Kim AY, Harzke AJ, et al. Impact of new therapeutics for hepatitis C virus infection in incarcerated populations. Topics Antiviral Med. 2013;21:27–35. PubMed PMC

Mitruka K, Tsertsvadze T, Butsashvili M, et al. Launch of a nationwide hepatitis C elimination program – Georgia, April 2015. MMWR CDC Surveillance Summaries. 2015;64:753–7. PubMed PMC

Westergaard RP, Spaulding AC, Flanigan TP. HIV among persons incarcerated in the USA: a review of evolving concepts in testing, treatment, and linkage to community care. Curr Opin Infect Dis. 2013;26:10–6. PubMed PMC

Small W, Wood E, Betteridge G, Montaner J, Kerr T. The impact of incarceration upon adherence to HIV treatment among HIV-positive injection drug users: a qualitative study. AIDS Care. 2009;21:708–14. PubMed

Milloy MJ, Kerr T, Buxton J, et al. Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis. 2011;203:1215–21. PubMed PMC

Westergaard RP, Kirk GD, Richesson DR, Galai N, Mehta SH. Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy. Clin Infect Dis. 2011;53(7):725–31. PubMed PMC

Werb D, Milloy MJ, Kerr T, Zhang R, Montaner J, Wood E. Injection drug use and HIV antiretroviral therapy discontinuation in a Canadian setting. AIDS Behav. 2013;17:68–73. PubMed PMC

Wakeman SE, Rich JD. HIV treatment in US prisons. HIV Therapy. 2010;4:505–10. PubMed PMC

Jurgens R. Interventions to address HIV in prison (Evidence for Action series) Geneva: World Health Organization; 2007.

Culbert G, Bazazi A, Waluyo A, et al. The Influence of Medication Attitudes on Utilization of Antiretroviral Therapy (ART) in Indonesian Prisons. AIDS Behav. 2015:1–13. PubMed PMC

Todrys KW, Amon JJ, Malembeka G, Clayton M. Imprisoned and imperiled: access to HIV and TB prevention and treatment, and denial of human rights, in Zambian prisons. J Int AIDS Soc. 2011;14:8. PubMed PMC

Shalihu N, Pretorius L, van Dyk A, Vander Stoep A, Hagopian A. Namibian prisoners describe barriers to HIV antiretroviral therapy adherence. AIDS Care. 2014;26:968–75. PubMed

Chakrapani V, Kamei R, Kipgen H, Kh JK. Access to harm reduction and HIV-related treatment services inside Indian prisons: experiences of formerly incarcerated injecting drug users. Int J Prison Health. 2013;9(2):82–91. PubMed

Alpert M, Wickersham JA, Vazquez M, Altice FL. Alcohol use disorders and antiretroviral therapy among prisoners in Argentina. Int J Prison Health. 2013;9:40–50. PubMed PMC

Prellwitz IM, Alves BM, Ikeda ML, et al. HIV behind bars: human immunodeficiency virus cluster analysis and drug resistance in a reference correctional unit from southern Brazil. PLoS One. 2013;8(7):e69033. PubMed PMC

Wilson D, Ford N, Ngammee V, Chua A, Kyaw MK. HIV prevention, care, and treatment in two prisons in Thailand. PLoS Med. 2007;4(6):e204. PubMed PMC

World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: 2011.

Dara M, Acosta CD, Melchers NV, et al. Tuberculosis control in prisons: current situation and research gaps. Int J Infect Dis. 2015;32:111–7. PubMed

Lee D, Lal SS, Komatsu R, Zumla A, Atun R. Global fund financing of tuberculosis services delivery in prisons. J Infect Dis. 2012;205(Suppl 2):S274–83. PubMed

Iroh PA, Mayo H, Nijhawan AE. The HIV Care Cascade Before, During, and After Incarceration: A Systematic Review and Data Synthesis. Am J Public Health. 2015;105(7):e5–16. PubMed PMC

Pan American Health Organization. Improving access of key populations to comprehensive HIV Health Services: Towards a Caribbean consensus. Washington, DC: PAHO; 2011.

Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M. Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ. 2013;91:102–23. PubMed PMC

World Health Organization. Community management of opioid overdose. Geneva: 2014. PubMed

Quan VM, Minh NL, Ha TV, et al. Mortality and HIV transmission among male Vietnamese injection drug users. Addiction. 2011;106:583–9. PubMed PMC

Vanichseni S, Martin M, Suntharasamai P, et al. High mortality among non-HIV-infected people who inject drugs in Bangkok, Thailand, 2005–2012. Am J Public Health. 2015;105(6):1136–41. PubMed PMC

van Amsterdam J, van den Brink W. The misuse of prescription opioids: a threat for europe? Current Drug Abuse rev. 2015;8:3–14. PubMed

Polomeni P, Schwan R. Management of opioid addiction with buprenorphine: French history and current management. Int J Gen Med. 2014;7:143–8. PubMed PMC

Paone D, Tuazon E, Stajic M, et al. Buprenorphine infrequently found in fatal overdose in New York City. Drug Alcohol Dep. 2015;155:298–301. PubMed

Hammersley R, Cassidy MT, Oliver J. Drugs associated with drug-related deaths in Edinburgh and Glasgow, November 1990 to October 1992. Addiction. 1995;90:959–65. PubMed

Matusow H, Dickman SL, Rich JD, et al. Medication assisted treatment in US drug courts: Results from a nationwide survey of availability, barriers and attitudes. J Subst Abuse Treatment. 2013;44:473–80. PubMed PMC

Cole C, Jones L, McVeigh J, Kicman A, Syed Q, Bellis M. Adulterants in illicit drugs: a review of empirical evidence. Drug Festing Analysis. 2011;3:89–96. PubMed

Mounteney J, Giraudon I, Denissov G, Griffiths P. Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe. Int J Drug Policy. 2015;26:626–31. PubMed

Farrell M, Hall W. Heroin-assisted treatment: has a controversial treatment come of age? Br J Psychiatry. 2015;207:3–4. PubMed

Bohnert ASB, Nandi A, Tracy M, et al. Policing and risk of overdose mortality in urban neighborhoods. Drug Alcohol Dep. 2011;113:62–8. PubMed PMC

Farrell M, Marsden J. Acute risk of drug-related death among newly released prisoners in England and Wales. Addiction. 2008;103:251–5. PubMed

European Monitoring Centre for Drugs and Drug Abuse (EMCDDA) Perspectives on drugs: preventing overdose deaths in Europe. Lisbon: 2015.

Carter C, G B. Opioid overdose prevention and response in Canada. Vancouver: Canadian Drug Policy Coalition; 2013.

Marshall BD, Milloy MJ, Wood E, Montaner JS, Kerr T. Reduction in overdose mortality after the opening of North America’s first medically supervised safer injecting facility: a retrospective population-based study. Lancet. 2011;377:1429–37. PubMed

Kerr T, Stoltz JA, Tyndall M, et al. Impact of a medically supervised safer injection facility on community drug use patterns: a before and after study. BMJ (Clinical Research Ed) 2006;332:220–2. PubMed PMC

Kerr T, Tyndall MW, Zhang R, Lai C, Montaner JS, Wood E. Circumstances of first injection among illicit drug users accessing a medically supervised safer injection facility. Am J Public Health. 2007;97:1228–30. PubMed PMC

Wood E, Tyndall MW, Lai C, Montaner JS, Kerr T. Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crime. Subst Abuse Treatment Prev Policy. 2006;1:13. PubMed PMC

Alexander L, Mannion RO, Weingarten B, Fanelli RJ, Stiles GL. Development and impact of prescription opioid abuse deterrent formulation technologies. Drug Alcohol Dep. 2014;138:1–6. PubMed

Degenhardt L, Larance B, Bruno R, Lintzeris N, Ali R, Farrell M. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol. Addiction. 2015;110:226–37. PubMed

Delcher C, Wagenaar AC, Goldberger BA, Cook RL, Maldonado-Molina MM. Abrupt decline in oxycodone-caused mortality after implementation of Florida’s Prescription Drug Monitoring Program. Drug Alcohol Dep. 2015;150:63–8. PubMed

Cassidy TA, DasMahapatra P, Black RA, Wieman MS, Butler SF. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation. Pain Med. 2014;15:440–51. PubMed

Leece P, Orkin AM, Kahan M. Tamper-resistant drugs cannot solve the opioid crisis. CMAJ (Ottawa) 2015;187:717–8. PubMed PMC

Network for Public Health Law. Legal interventions to reduce overdose mortality: naloxone access and overdose Good Samaritan laws. St Paul, MN (USA): 2015.

Davis CS, Carr D, Southwell JK, Beletsky L. Engaging law enforcement in overdose reversal initiatives: authorization and liability for naloxone administration. Am J Public Health. 2015;105:1530–7. PubMed PMC

Hammett TM, Phan S, Gaggin J, et al. Pharmacies as providers of expanded health services for people who inject drugs: a review of laws, policies, and barriers in six countries. BMC Health Serv Res. 2014;14:261. PubMed PMC

Gallant J. Drug addiction: Ontario buys naloxone, an overdose life-saver, and then locks it up. Star (Toronto) 2013 Jul 29; http://www.thestar.com/news/gta/2013/07/29/drug_addiction_ontario_buys_naloxone_an_overdose_lifesaver_then_locks_it_up.html (accessed 4 Sept 2015)

CVS pharmacy expands naloxone access in 12 more states. Pharmacist. 2015 Sep 24; At: http://www.pharmacist.com/cvspharmacy-expands-naloxone-access-12-more-states (accessed 5 Oct 2015)

Drug Policy Alliance. Federal lawmakers introducing naloxone prevention bill to combat heroin and opioid overdose crisis (press statement) New York: 2015. http://www.drugpolicy.org/news/2015/06/federal-lawmakers-introducing-overdose-prevention-bill-combat-heroin-and-opioid-overdos (accessed 15 September 2015)

Human Rights Watch. Torture in the name of treatment: Human rights abuses in Vietnam, China, Cambodia and Lao PDR. New York: 2012.

World Health Organization Western Pacific Regional Office. Assessment of compulsory treatment of people who use drugs in Cambodia, China, Malaysia and Viet Nam: an application of selected human rights principles. Manila: 2009.

International Labour Organization, UN Development Programme, UNAIDS. Joint statement: Compulsory drug detention and rehabilitation centres. Geneva: United Nations; 2012.

Saucier R, Wolfe D. Center for Human Rights and Humanitarian Law Torture in health care settings: reflection on the Special Rapporteur on Torture’s 2013 report. Washington, DC: American University; 2014. Privatizing cruelty—torture, inhumane and degrading Treatment in non-governmental drug rehabilitation centers.

United Nations Office on Drugs and Crime. From coercion to cohesion: treating drug dependence through health care, not punishment. Vienna: 2009.

O’Neill KL. On Liberation Crack, Christianity, and Captivity in Postwar Guatemala City. Social Text. 2014;32:11–28.

Wolfe D. Death, drug treatment, and Christ’s love (online) New York: Open Society Foundations; 2012.

Human Rights Watch. ‘Like a death sentence’: abuses against persons with mental disabilities in Ghana. New York: 2012.

Mendez J. Report of the Special Rapporteur on torture and other cruel, inhuman or degrading treatment or punishment, Addendum: mission to Ghana. 2014. (UN doc. A/HRC/25/60/Add.1).

Sun HM, Li XY, Chow EP, et al. Methadone maintenance treatment programme reduces criminal activity and improves social well-being of drug users in China: a systematic review and meta-analysis. BMJ Open. 2015;5(1):e005997. PubMed PMC

Dennis BB, Naji L, Bawor M, et al. The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol. Syst Rev. 2014;3:105. PubMed PMC

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Guidelines for the treatment of drug dependence: a European perspective. Lisbon: 2011.

Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev. 2003;(3):Cd002208. PubMed

Fareed A, Casarella J, Amar R, Vayalapalli S, Drexler K. Methadone maintenance dosing guideline for opioid dependence, a literature review. J Addict Dis. 2010;29:1–14. PubMed

Fareed A, Casarella J, Roberts M, et al. High dose versus moderate dose methadone maintenance: is there a better outcome? J Addict Dis. 2009;28:399–405. PubMed

Lambdin BH, Masao F, Chang O, et al. Methadone treatment for HIV prevention—feasibility, retention, and predictors of attrition in Dar es Salaam, Tanzania: a retrospective cohort study. Clin Infect Dis. 2014;59:735–42. PubMed PMC

Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL. Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction. 2005;100:1496–509. PubMed

World Health Organization Regional Office for the Western Pacific. Clinical guidelines for withdrawal management and treatment of drug dependence in closed settings. Manila: 2009. PubMed

Nordt C, Stohler R. Incidence of heroin use in Zurich, Switzerland: a treatment case register analysis. Lancet. 2006;367:1830–4. PubMed

Fischer B, Oviedo-Joekes E, Blanken P, et al. Heroin-assisted treatment (HAT) a decade later: a brief update on science and politics. J Urban Health. 2007;84:552–62. PubMed PMC

Fischer B, Murphy Y, Rudzinski K, MacPherson D. Illicit drug use and harms, and related interventions and policy in Canada: A narrative review of select key indicators and developments since 2000. Int J Drug Policy. 2015 PubMed

Keller J. Judge grants injunction allowing doctors to prescribe heroin to group of Vancouver addicts. National Post. 2014

Csete J. Costs and benefits of drug-related health services. In: Collins J, editor. Ending the drug wars: report of the LSE Expert Group on the Economics of Drug Policy. London: London School of Economics; 2014. pp. 70–6.

Basu A, Paltiel AD, Pollack HA. Social costs of robbery and the cost-effectiveness of substance abuse treatment. Health Econ. 2008;17:927–46. PubMed PMC

McCollister KE, French MT. The relative contribution of outcome domains in the total economic benefit of addiction interventions: a review of first findings. Addiction. 2003;98:1647–59. PubMed

Xing Y, Sun J, Cao W, et al. Economic evaluation of methadone maintenance treatment in HIV/AIDS control among injecting drug users in Dehong, China. AIDS Care. 2012;24:756–62. PubMed

Ni MJ, Fu LP, Chen XL, Hu XY, Wheeler K. Net financial benefits of averting HIV infections among people who inject drugs in Urumqi, Xinjiang, Peoples Republic of China (2005–2010) BMC Public Health. 2012;12:572. PubMed PMC

Dursteler KM, Berger EM, Strasser J, et al. Clinical potential of methylphenidate in the treatment of cocaine addiction: a review of the current evidence. Subst Abuse Rehab. 2015;6:61–74. PubMed PMC

Laudet AB, White W. What are your priorities right now? Identifying service needs across recovery stages to inform service development. J Subst Abuse Treat. 2010;38:51–9. PubMed PMC

de Jesus Mari J, Tofoli LF, Noto C, et al. Pharmacological and psychosocial management of mental, neurological and substance use disorders in low- and middle-income countries: issues and current strategies. Drugs. 2013;73:1549–68. PubMed

Metz VE, Brandt L, Unger A, Fischer G. Substance abuse/dependence treatment: a European perspective. Subst Abuse. 2014;35:309–20. PubMed

Andrews C, Abraham A, Grogan CM, et al. Despite Resources From The ACA, Most States Do Little To Help Addiction Treatment Programs Implement Health Care Reform. Health Affairs. 2015;34:828–35. PubMed PMC

Burns K. Women, harm reduction and HIV: key findings from Azerbaijan, Georgia, Kyrgyzstan, Russia and Ukraine. New York: Open Society Foundations; 2009.

Kenny KS, Barrington C, Green SL. “I felt for a long time like everything beautiful in me had been taken out”: Women’s suffering, remembering, and survival following the loss of child custody. Int J Drug Policy. 2015;26:1158–66. PubMed

De Bortoli L, Coles J, Dolan M. Linking illicit substance misuse during pregnancy and child abuse: what is the quality of the evidence? Child Family Social Work. 2014;19:136–48.

Crime UNOoDa. Substance abuse treatment and care for women: case studies and lessons learned. Vienna: 2004.

Mayes LC, Granger RH, Bornstein MH, Zuckerman B. The problem of prenatal cocaine exposure. A rush to judgment. JAMA. 1992;267(3):406–8. PubMed

Hurt H, Betancourt LM, Malmud EK, et al. Children with and without gestational cocaine exposure: a neurocognitive systems analysis. Neurotoxicol Teratol. 2009;31:334–41. PubMed PMC

Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363:2320–31. PubMed PMC

Abrahams R, Albizu-Garcia C, Bakker A, et al. Open letter regarding alarmist and inaccurate reporting on prescription opioid use by pregnant women. 2013

Roberts A, Mathers B, Degenhardt L. Women who inject drugs: A review of their risks, experiences and needs A report prepared on behalf of the Reference Group to the United Nations on HIV and Injecting Drug Use. Sydney: National Drug and Alcohol Research Centre (NDARC), University of New South Wales; 2010.

International Narcotics Control Board. Annual report for 2014. Vienna: 2014.

World Health Organization. Ensuring balance in national policies on controlled substances: guidance for availability and accessibility of controlled medicines. Geneva: 2011.

Pain & Policy Studies Group. Achieving balance in state pain policy: A progress report card (CY 2013) University of Wisconsin Carbone Cancer Center; Madison, Wisconsin: 2014.

Cherny NI, Baselga J, de Conno F, Radbruch L. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative. Ann Oncol. 2010;21:615–26. PubMed

Republic of India. Narcotic Drugs and Psychotropic Substances Act 1985. 1985. p. 16. (Enactment no. 61).

Global Commission on Drug Policy. The negative impact of drug control on public health: the global crisis of avoidable pain. Rio de Janeiro: 2015.

Bandewar SV. Access to controlled medicines for palliative care in India: gains and challenges. Indian J Med Ethics. 2015;12:77–82. PubMed

Human Rights Watch. World report 2014 (India chapter) New York: 2014.

Mohapatra S, Rath N. Appraisal of the narcotic drugs and psychotropic substances (amendment) act, 2014. Asian J Psychiatry. 2015;14:80–1. PubMed

United Nations Convention on psychotropic substances. Vienna: 1971.

Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet. 2007;369:1047–53. PubMed

Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. Lancet. 2010;376:1558–65. PubMed

van Amsterdam J, Nutt D, Phillips L, van den Brink W. European rating of drug harms. J Psychopharmacol. 2015;29:655–60. PubMed

Hall W, Carter A, Forlini C. The brain disease model of addiction: challenging or reinforcing stigma? Authors’ reply. Lancet Psychiatry. 2015;2:292. PubMed

Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313:2456–73. PubMed

Deshpande A, Mailis-Gagnon A, Zoheiry N, Lakha SF. Efficacy and adverse effects of medical marijuana for chronic noncancer pain: Systematic review of randomized controlled trials. Can Family Physician. 2015;61:e372–81. PubMed PMC

Madras B. Update of cannabis and its medical use Review for the 37th session of the WHO Expert Committee on Drug Dependence. Geneva: WHO; 2015.

World Health Organization, Expert Committee on Drug Dependence. Extract from the Report of the 37th Expert Committee on Drug Dependence, convened from 16 to 20 November 2015 at WHO headquarters in Geneva. Commission on Narcotic Drugs; 2015.

Hall W, Weier M. Assessing the public health impacts of legalizing recreational cannabis use in the USA. Clin Pharmacol Ther. 2015;97:607–15. PubMed

Shen H. Federal red tape ties up marijuana research. Nature. 2014;507:407–8. PubMed

Pacula RL, Powell D, Heaton P, Sevigny EL. Assessing the effects of medical marijuana laws on marijuana use: the devil is in the details. J Policy Analysis Mgt. 2015;34:7–31. PubMed PMC

Bachhuber MA, Saloner B, Cunningham CO, Barry CL. MEdical cannabis laws and opioid analgesic overdose mortality in the united states, 1999–2010. JAMA Internal Med. 2014;174:1668–73. PubMed PMC

University of New South Wales. Injecting drug users reference group: The Reference Group to the UN on HIV and Drug Use (online introduction) https://ndarc.med.unsw.edu.au/project/injecting-drug-users-reference-group-reference-group-un-hiv-and-injecting-drug-use (accessed 14 October 2015)

Degenhardt L, Larance B, Mathers B, et al. on behalf of the Reference Group to the United Nations on HIV and injecting drug use Benefits and risks of pharmaceutical opioids: Essential treatment and diverted medication . A global review of availability, extra-medical use, injection and the association with HIV. Sydney: National Drug and Alcohol Research Centre, University of New South Wales; 2007. (Reference Group Thematic Paper Series).

Degenhardt L, Mathers B, Guarinieri M, et al. on behalf of the Reference Group to the United Nations on HIV and injecting drug use . The global epidemiology of methamphetamine injection: A review of the evidence on use and associations with HIV and other harm. Sydney: National Drug and Alcohol Research Centre, University of New South Wales; 2007. (Reference Group Thematic Paper Series).

Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375:1014–28. PubMed

Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372:1733–45. PubMed

Degenhardt L, Mathers B, Guarinieri M, et al. Meth/amphetamine use and associated HIV: Implications for global policy and public health. Int J Drug Policy. 2010;21:347–58. PubMed

UN Development Programme. Request for proposals: national survey on drug use in Nigeria. 2014 May; http://procurement-notices.undp.org/view_file.cfm?doc_id=29568 (accessed 16 September 2015)

Buxton J. Drugs and development: The great disconnect. Global Drug Policy Observer (Swansea), Policy Report no 2. 2015 http://www.swansea.ac.uk/media/The%20Great%20Disconnect.pdf (accessed 24 Sept 2015)

United Nations Office on Drugs and Crime. Southeast Asia opium survey 2014 Lao PDR. Myanmar, Bangkok: 2014.

Fishstein P. Despair or hope: rural livelihoods and opium poppy dynamics in rural Afghanistan. Kabul: Afghanstan Research and Evaluation Unit; 2014.

Mansfield D. Assessing supply-side policy and practice: eradication and alternative development. Global Commission on Drug Policy Working Paper. 2011

Mejía D, Restrepo P, Rozo SV. On the effects of enforcement on illegal markets: evidence from a quasi-experiment in Colombia. Bogotá: Universidad de los Andes; 2014.

Chouvy PA, Afsahi K. Hashish revival in Morocco. Int J Drug Policy. 2014;25:416–23. PubMed

United Nations Office on Drugs and Crime (UNODC) Government of Colombia. Colombia coca cultivation survey 2013. Bogotá: 2014.

Mansfield D, Pain A. Alternative livelihoods: substance or slogan? (briefing paper) Kabul: Afghanstan Research and Evaluation Unit; 2005.

Camacho A, Mejía D. The health consequences of aerial spraying of illicit crops: the case of Colombia (Working Paper 408) Washington, DC: Center for Global Development; 2015. http://www.cgdev.org/publication/health-consequences-aerial-spraying-illicit-crops-case-colombia-working-paper-408 (accessed 29 Sept 2015)

Mejía D. Plan Colombia: an analysis of effectiveness and costs. Brookings Institution; 2015. (Improving Global Drug Policy series).

United Nations Office on Drugs and Crime, Plurinational State of Bolivia. Estado Plurinacional de Bolivia: Monitoreo de cultivos de coca 2014. La Paz: 2015.

United Nations Office on Drugs and Crime, Government of Colombia. Colombia coca cultivation survey 2014. Bogota: 2015.

United Nations Office on Drugs and Crime, National Drug Commission of Peru. Peru: Monitoreo de cultivas de coca 2014. Lima: 2015.

Solomon KR, Anadón A, Cerdeira AL, Marshall J, Sanin L-H. Environmental and human health assessment of the aerial spray program for coca and poppy control in Colombia. Prepared for the Inter-American Drug Abuse Control Commission section of the Organization of American States; Washington, DC: 2005.

Transnational Institute. The CICAD study on the impacts of glyphosate and the crop figures: the politics of glyphosate. Amsterdam: 2005. (Drug Policy Briefing no 14).

Rincón-Ruiz A, Kallis G. Caught in the middle, Colombia’s war on drugs and its effects on forest and people. Geoforum. 2013;46:60–78.

Republic of Ecuador. Application instituting proceedings submitted to International Court of Justice. 2008. (General List no 138).

Menendez A. Ecuador-Colombia settlement won’t end spraying. Inter Press Service. 2013 http://www.ipsnews.net/2013/10/ecuador-colombia-settlement-wont-end-spraying/ (accessed 2 October 2015)

Guyton KZ, Loomis D, Grosse Y, et al. Carcinogenicity of tetrachlorvinphos, parathion, malathion, diazinon, and glyphosate. Lancet Oncol. 2015;16:490–1. PubMed

World Health Organization International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans: Preamble. Lyon, France: 2006.

Ospina GA. A new challenge for the Santos Administration: Colombia’s end to the aerial coca eradication program. Washington, DC: Council on Hemispheric Affairs; 2015.

Salisbury DS, Fagan C. Coca and conservation: cultivation, eradication, and trafficking in the Amazon borderlands. GeoJournal. 2013;78:41–60.

UN Women. A gender perspective on the impact of drug use, the drug trade, and drug control regimes: UN Women policy brief. New York: 2014.

German Federal Ministry for Economic Cooperation and Development (BMZ) Rethinking the approach of alternative development: principles and standards of rural development in drug producing areas. Berlin: GIZ (Deutsche Gesellschaft für Internationale Zusammenarbeit); 2013.

Klantschnig G. The politics of law enforcement in Nigeria: lessons from the war on drugs. J Modern Afr Stud. 2009;47:529–49.

McSweeney K, Nielsen EA, Taylor MJ, et al. Conservation. Drug policy as conservation policy: narco-deforestation. Science. 2014;343:489–90. PubMed

Rozen L. Holbrooke: I’ve changed Bush’s failed Afghan drug policy. Foreign Policy (blog) 2009 Jul 30; http://foreignpolicy.com/2009/07/30/holbrooke-ive-changed-bushs-failed-afghan-drug-policy/ (accessed 29 September 2015)

Domosławski A. Drug policy in Portugal: the benefits of decriminalizing drug use. New York: Open Society Foundations Global Drug Policy Program; 2011.

Hughes CE, Stevens A. What can we learn from the Portuguese decriminalization of illicit drugs? Br J Criminol. 2010:azq083.

Goulão J. National drug policy director, Portugal. 2015 personal communication.

Hughes CE, Stevens A. A resounding success or a disastrous failure: re-examining the interpretation of evidence on the Portuguese decriminalisation of illicit drugs. Drug Alcohol rev. 2012;31:101–13. PubMed

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Statistical bulletin. 2011 http://www.emcdda.europa.eu/stats11 (accessed September 29 2015)

Csete J, Grob PJ. Switzerland, HIV and the power of pragmatism: lessons for drug policy development. Int J Drug Policy. 2012;23:82–6. PubMed

Csete J. From the mountaintops: what the world can learn from drug policy change in Switzerland. New York: Open Society Foundations; 2010.

Bozicevic I, Handanagic S, Lepej SZ, Begovac J. The emerging and re-emerging human immunodeficiency virus epidemics in Europe. Clin Microbiol Infect. 2013;19(10):917–29. PubMed

Rihs-Middel M, Hämmig R, Jacobshagen N. Heroin-assisted treatment: work in progress. Bern: Swiss Federal Office of Public Health; 2005.

Güttinger F, Gschwend P, Schulte B, Rehm J, Uchtenhagen A. Evaluating long-term effects of heroin-assisted treatment: the results of a 6-year follow-up. Eur Addiction Res. 2003;9:73–9. PubMed

Rehm J, Frick U, Hartwig C, Gutzwiller F, Gschwend P, Uchtenhagen A. Mortality in heroin-assisted treatment in Switzerland 1994–2000. Drug Alcohol Dep. 2005;79:137–43. PubMed

Strang J, Groshkova T, Uchtenhagen A, et al. Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addictiondagger. Br J Psychiatry. 2015;207:5–14. PubMed

Withnall A. Switzerland changes law to decriminalise marijuana possession. Independent (UK) 2013 Oct 3; 2013. http://www.independent.co.uk/news/world/europe/switzerland-changes-law-to-decriminalise-marijuana-possession-8856308.html (accessed September 30 2015)

Kalina K. Developing the system of drug services in the Czech Republic. J Drug Issues. 2007;37:181–204.

Zábranský T. Czech drug laws as an arena of drug policy battle. J Drug Issues. 2004;34:661–86.

Csete J. A balancing act: policymaking on illicit drugs in the Czech Republic. New York: Open Society Foundation; 2011.

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Alternatives to punishment for drug using offenders. Lisbon: 2015.

Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997;11:F59–65. PubMed

Wood E, Kerr T. What do you do when you hit rock bottom? Responding to drugs in the city of Vancouver. Int J Drug Policy. 2006;17:55–60.

Tyndall MW, Currie S, Spittal P, et al. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS. 2003;17:887–93. PubMed

Urban Health Research Initiatie, University of British Columbia. Drug situation in Vancouver. Vancouver: Urban Health Research Initiative; 2009.

Kerr T, Small W, Buchner C, et al. Syringe sharing and HIV incidence among injection drug users and increased access to sterile syringes. Am J Public Health. 2010;100:1449–53. PubMed PMC

Hayashi K, Wood E, Wiebe L, Qi J, Kerr T. An external evaluation of a peer-run outreach-based syringe exchange in Vancouver, Canada. Int J Drug Policy. 2010;21:418–21. PubMed PMC

Wood E, Kerr T, Marshall BDL, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ (Clinical Research Ed) 2009;338 PubMed PMC

Kerr T, Tyndall M, Li K, Montaner J, Wood E. Safer injection facility use and syringe sharing in injection drug users. Lancet. 2005;366:316–8. PubMed

Bayoumi AM, Zaric GS. The cost-effectiveness of Vancouver’s supervised injection facility. CMAJ (Ottawa) 2008;179:1143–51. PubMed PMC

Canada (Attorney General) v PHS Community Services Society. 2011

Tran OC, Bruce RD, Masao F, et al. Implementation and operational research: linkage to care among methadone clients living with HIV in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr. 2015;69:e43–e8. PubMed PMC

Gupta A, Mbwambo J, Mteza I, et al. Active case finding for tuberculosis among people who inject drugs on methadone treatment in Dar es Salaam, Tanzania. Int J Tuberc Lung Dis. 2014;18:793–8. PubMed PMC

United Nations Office on Drugs and Crime. Drug use and trafficking in Senegal: strengthening monitoring and treatment centres (online statement) 2014 https://www.unodc.org/westandcentralafrica/en/senegal—drug-monitoring-and-rehabilitation.html (accessed 28 September 2015)

Arroyo-Cobo JM. Public health gains from health in prisons in Spain. Public Health. 2010;124:629–31. PubMed

Hoover J, Jürgens R. Harm reduction in prison: the Moldova model. New York: Open Society Institute; 2009.

Doltu S. Presentation to the UNAIDS Programme Coordination Board. Geneva: 2015. http://www.unaids.org/sites/default/files/media_asset/20151012_UNAIDS_PCB37_15-21_EN.pdf (accessed 14 dec 2015)

Open Society Foundations. Stopping overdose: peer-based distribution of naloxone. New York: 2013.

Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal in Russian cities. J Medical Econ. 2013;16:1051–60. PubMed

Bird SM, Parmar MKB, Strang J. Take-home naloxone to prevent fatalities from opiate-overdose: Protocol for Scotland’s public health policy evaluation, and a new measure to assess impact. Drugs Educ Prev Policy. 2014;22:66–76. PubMed PMC

Watt G, Jaquet S, Ellison S, Christie I, Nicholson J. Service evaluation of Scotland’s national take-home naloxone programme. Scottish Government Social Research. 2014

Stöver HJ, Schäffer D. SMOKE IT! Promoting a change of opiate consumption pattern-from injecting to inhaling. Harm Reduct J. 2014;11(18):1–8. PubMed PMC

Kamarulzaman A, McBrayer JL. Compulsory drug detention centers in East and Southeast Asia. Int J Drug Policy. 2015;26:S33–S7. PubMed

Ghani MA, Brown S-E, Khan F, et al. An exploratory qualitative assessment of self-reported treatment outcomes and satisfaction among patients accessing an innovative voluntary drug treatment centre in Malaysia. Int J Drug Policy. 2015;26:175–82. PubMed PMC

Amon JJ, Pearshouse R, Cohen JE, Schleifer R. Compulsory drug detention in East and Southeast Asia: evolving government, UN and donor responses. Int J Drug Policy. 2014;25(1):13–20. PubMed

UNAIDS. Alternative action on compulsory detention: innovative responses in Asia (press statement) 2012 Oct 5; http://www.unaids.org/en/resources/presscentre/featurestories/2012/october/20121005detentioncenters/ (accessed 9 October 2015)

Stolberg VB. The use of coca: prehistory, history, and ethnography. J Ethnicity Subst Abuse. 2011;10:126–46. PubMed

United Nations Office on Drugs and Crime. Bolivia to re-acceded to UN drug convention while making exception on coca leaf chewing (media statement) 2013 https://www.unodc.org/unodc/en/frontpage/2013/January/bolivia-to-re-accede-to-un-drug-convention-while-making-exception-on-coca-leaf-chewing.html (accessed 23 September 2015)

Ledebur K, Youngers CA. From Conflict to Collaboration: An Innovative Approach to Reducing Coca Cultivation in Bolivia. Stability. 2013;2(1) Art. 9.

International Covenant on Civil and Political Rights. UNGA res. 1966 Dec 16;2200A(XXI)

Siracusa principles on the limitation and derogation provisions in the International Covenant on Civil and Political Rights. UN doc. E/CN.4/1985/4 Annex. 1985

United Nations Office on Drugs and Crime. Making drug control ‘fit for purpose’: Building on the UNGASS decade. Vienna: 2008.

Caulkins JP. Effects of prohibition, enforcement and interdiction on drug use Ending the drug wars: report of the LSE Expert Group on the Economics of Drug Policy. London: London School of Economics; 2014. pp. 16–25.

Piot P, Abdool Karim SS, Hecht R, et al. Defeating AIDS—advancing global health. The Lancet. 2015;386:171–218. PubMed

Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis